China SXT Pharmaceuticals
SXTC
4 hedge funds and large institutions have $30K invested in China SXT Pharmaceuticals in 2024 Q3 according to their latest regulatory filings, with 2 funds opening new positions, increasing their positions, 1 reducing their positions, and 3 closing their positions.
0.01% less ownership
Funds ownership: 0.01% → 0% (-0.01%)
20% less funds holding
Funds holding: 5 → 4 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
63% less capital invested
Capital invested by funds: $79.9K → $30K (-$50K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
|
+$14.1K |
| 2 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$10.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
-$34K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$17.4K |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$3.25K |
| 4 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.17K |
| 5 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
-$327 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GCP
1
GSA Capital Partners
London,
United Kingdom
| $9K | +$10.8K | +10 | New |
|
|
BBA
2
Baader Bank Aktiengesellschaft
Unterschleissheim,
Germany
| $7.93K | +$14.1K | +13 | New |
|
3
Bank of Montreal
Toronto,
Ontario, Canada
| $6.42K | – | – | – |
|
|
4
UBS Group
Zurich,
Switzerland
| $6.33K | -$3.25K | -3 | -30% |
|
5
JP Morgan Chase
New York
| $274 | – | – | – |
|
|
VF
6
Virtu Financial
New York
| – | -$34K | -26 | Closed |
|
|
7
Citadel Advisors
Miami,
Florida
| – | -$17.4K | -13 | Closed |
|
|
8
Acadian Asset Management
Boston,
Massachusetts
| – | -$2.17K | -2 | Closed |
|
|
9
Qube Research & Technologies (QRT)
London,
United Kingdom
| – | -$327 | – | – |
|
SXTC Hedge Fund Activity: Q3 2024 in Review
4 of the 6,967 institutional investors tracked by Wall St. Rank reported a position in China SXT Pharmaceuticals (SXTC) for Q3 2024, worth a combined $30K — down 63% from $79.9K a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of SXTC and 2 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 0 added.
The largest buyer was Baader Bank Aktiengesellschaft, opening a new position worth an estimated $14.1K. The largest seller was Virtu Financial, exiting entirely with an estimated $34K sold.
- 4 institutional investors held China SXT Pharmaceuticals (SXTC) as of Q3 2024, down from 5 in Q2 2024.
- Funds reported $30K of China SXT Pharmaceuticals stock for Q3 2024, down 63% quarter-over-quarter.
- 2 funds opened new China SXT Pharmaceuticals positions in Q3 2024 and 3 closed out, a net change of -1 holder.
- The largest China SXT Pharmaceuticals buyer in Q3 2024 was Baader Bank Aktiengesellschaft, an estimated $14.1K added.
- The largest China SXT Pharmaceuticals seller in Q3 2024 was Virtu Financial, an estimated $34K sold.
Based on aggregated 13F filings for Q3 2024.